Last reviewed · How we verify
Probiatop
Probiatop, marketed by Casa Espirita Terra de Ismael, is a probiotic product with a key composition patent expiring in 2028. The drug's market position and primary indication are not specified, but the patent protection provides a competitive advantage until expiry. The lack of detailed revenue and clinical trial data poses a significant risk in assessing its market performance and therapeutic efficacy.
At a glance
| Generic name | Probiatop |
|---|---|
| Also known as | Probiotics, Probiotic |
| Sponsor | Casa Espirita Terra de Ismael |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Efficacy And Safety Of Probiatop In The Treatment Of Digestive Symptoms (PHASE4)
- Trial on Effectiveness Combined Probiotics in Atopic Dermatitis in Children (PHASE4)
- Effects of Probiotic on Modulation of the Intestinal Microbiota in Constipated Patients (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Probiatop CI brief — competitive landscape report
- Probiatop updates RSS · CI watch RSS
- Casa Espirita Terra de Ismael portfolio CI